Dick Durbin charged in an unusually sharp attack today that the acting FDA commissioner seemed to have 'no intention' of addressing youth e-cigarette use, which his predecessor deemed a public health epidemic
Sen. Dick Durbin charged in an unusually sharp attack Wednesday that acting FDA Commissioner Ned Sharpless seemed to have "no intention" of addressing youth e-cigarette use, which his predecessor deemed a public health epidemic.
His May 14 meeting with Sharpless was "one of the most alarming and disappointing meetings in my time in public service," the No. 2 Senate Democrat to Sharpless, a longtime cancer researcher who took the top FDA post in April as Scott Gottlieb left.During the meeting, Durbin said, he pushed for FDA to move up the deadline to review e-cigarette products including kid-friendly vapors, but left theThe FDA in 2017 extended the review deadline to August 2022, then this March moved it up to 2021. A federal judge in Maryland this monthGet the latest on the health care fight, every weekday morning — in your inbox.
In a news release, the FDA said Sharpless was committed to tackling the epidemic of e-cigarette use by preventing youth access to flavored tobacco products and taking action against illegal marketing to minors. It said Sharpless would respond directly to Durbin about his letter. Durbin also called on the FDA to stop popular e-cigarette brand Juul from claiming that it helps traditional smokers quit with its "make the switch" ad campaign. The company has no evidence for such a claim, the senatorHe concluded by warning Sharpless not to repeat the error Gottlieb made in allowing teen vaping to go unchecked for too long.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
“Best if used by.FDA supports manufacturers’ use of the phrase “Best If Used By” to cut down on date confusion
Read more »
Is Tahini safe? More brands recalled over Salmonella outbreak linkThe FDA are advising people not to eat Karawan, El-Karawan, or SoCo labeled tahini products.
Read more »
FDA approves Novartis' $2.1 million gene therapy — making it the world's most expensive drugThe therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting 1 in every 11,000 live births.
Read more »
Gene therapy gets FDA approval -- and a $2 million price tagThe FDA approved a treatment for a genetic disease called spinal muscular atrophy that causes infants' muscles to waste away, potentially killing them before age 2. The price tag? $2.125 million for a one-time treatment.
Read more »
The FDA approves a gene therapy that is the most expensive drug in the worldThe gene therapy Zolgensma, priced at $2.1 million, treats infants with spinal muscular atrophy.
Read more »
Novartis' breast cancer treatment wins FDA approvalThe U.S. Food and Drug Administration (FDA) said on Friday that it had approved ...
Read more »
$2.1 million drug to treat rare genetic disease approved by FDAThe drug, Zolgensma, is being called a 'miracle drug' and will be used to treat children with spinal muscular atrophy, or SMA.
Read more »
FDA wants food expiration dates standardized with 'best if used by' to cut wasteResearch has shown that 'best if used by' – not, say not 'best by' or 'sell by' – helps shoppers better understand they don't need to throw foods out after the printed date passes if they're stored correctly.
Read more »
A new drug costs $2.1 million for children with a muscle-wasting diseaseA new drug for treating a rare disease in infants and toddlers is priced at $425,000 per year over five years and is poised to become the nation's most expensive drug.
Read more »
Buyer beware: So-called sexual enhancement pills sold online can be dangerous for menThe FDA is warning consumers to stay away from dietary supplements claiming to promote sexual enhancement, weight loss or bodybuilding because they may contain hidden ingredients.
Read more »